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Oral Presentations S161(3.5–255) and median prior therapies was 4 (0–9). 88% were classi-
fied as classic and 12% as overlap. Median follow-up of surviving
pts was 30.3 mos (1-70). NIH scores for key organs and global sever-
ity were compared to sub-specialist evaluations (SSE) and 10 contin-
uous outcome measures [Lee Symptom Scale; SF-36 (physical/
mental); FACT-BMT; HAP score (MAS/AAS), 2 min walk test,
grip strength, and joint ROM]. NIH scores were compared to cate-
gorical outcomes: intensity of immunosuppression scale (IIS), ther-
apeutic intent at enrollment (TI) and clinician 7-point global
assessment of change (CGA).
Table 1. NIH Scores
NIH Global Score N (%)1 5 mild 2 (1)
2 5 moderate 62 (33)
3 5 severe 125 (66)
NIH Organ Score N (%) NIH Organ Score N (%)
Skin Liver
0 5 none 42 (22) 0 5 none 91 (48)
1 5 mild 30 (16) 1 5 mild 64 (34)
2 5 moderate 46 (24) 2 5 moderate 34 (18)
3 5 severe 71 (38) 3 5 severe 0
Mouth Lungs
0 5 none 59 (31) 0 5 none 45 (24)
1 5 mild 104 (55) 1 5 mild 79 (42)
2 5 moderate 23 (12) 2 5 moderate 42 (22)
3 5 severe 3 (1.5) 3 5 severe 23 (12)
Eyes Joints and Fascia
0 5 none 33 (17) 0 5 none 75 (40)
1 5 mild 66 (35) 1 5 mild 40 (21)
2 5 moderate 69 (36) 2 5 moderate 55 (29)
3 5 severe 21 (11) 3 5 severe 19 (10)
GI Tract Genital (female
only n5 90)
0 5 none 107 (57) 0 5 none 46 (51)
1 5 mild 62 (33) 1 5 mild 13 (14)
2 5 moderate 14 (7) 2 5 moderate 13 (14)
3 5 severe 6 (3) 3 5 severe 18 (9)NIH - National Institutes of Health, N - number, GI - gastrointestinal.
Results: 125/189 had a severeNIH global score; mean number of in-
volved organs was 4.8 (1-8) with a mean average NIH score of 1.09
(0.14-2.14). NIH scores for skin, mouth, eyes and female genital cor-
responded to SSE scores and standard measures: skin % BSA, oral
Schubert score, and Schirmer’s test, each with two-sided P values of
\0.0001. Joints/fascia, skin, lungandNIHglobal scores showedhigh-
est number of significant associations with outcomes. Joints/fascia and
skin scores, but not lung,were significantly associatedwith IIS,TI, and
CGA.AverageNIH scores adjusted for gender, were highly associated
with SSE, IIS, TI and CGA. In univariate analyses, lung scores of 3 vs.
\3had3yearprojectedsurvivalof 28%(95%CI12-83%)vs. 87%(CI:
80-92%) respectively. In multivariate analysis, adjusting for demo-
graphic and clinical parameters [including known predictors of
cGVHD mortality: Karnofsky score (KS), platelet count, and biliru-
bin], the final model contained KS .80 vs.\80 (HR 5 0.43; p 5
0.025) and NIH lung score of 3 vs. 0-2 (HR5 8.9; p\0.0001).
Conclusions: High association of NIH scores with SSE suggests
they are appropriate for clinical and research assessment, perhaps
substituting for complex sub-specialist evaluations. In moderate to
severely affected pts high NIH lung score is the most powerful inde-
pendent predictor of poor survival. These results indicate the NIH
severity score is reliable for assessing cGVHD.28
EARLY CYTOMEGALOVIRUS REPLICATION AFTER ALLOGENEIC STEM
CELL TRANSPLANTATION IS ASSOCIATED WITH A DRAMATICALLY
REDUCED RELAPSE RISK IN ACUTE MYELOID LEUKEMIA PATIENTS:
EVIDENCE FOR A PUTATIVE VIRUS-VERSUS-LEUKEMIA EFFECT
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Cytomegalovirus (CMV) reactivation after allogeneic stem cell
transplantation (alloSCT) is commonly regarded as an adverse and po-
tentially hazardous event. In-vitro and animal data point to anti-tu-
moral effects of CMV infection, which may also play a role after
alloSCT. This prompted us to investigate the influence of early
CMV replication in 266 consecutive adult (median age [years]: 47,
19–73) acute myeloid leukemia (AML) patients (pts), who received
transplants from 10/10 high-resolution HLA-matched unrelated (n
5 148) or related (n 5 118) donors. Sixty-three % of pts (n 5 167)
were at risk for CMV replication based on either patient or donor pre-
transplant serostatus. After a median of 45 (25–108) days, first CMV
replication as detected by pp65 antigenemia assay occurred in 77
pts, of whom 4 pts had a seronegative patient and donor CMV seros-
tatus. Taking competing risks into account, the cumulative incidence
of hematologic relapse (CIR) at 10 years after alloSCT was 42 % (95
%confidence limit [95%CL]: 35–51) in pts without compared to 9%
(95 % CL: 4–19) in pts with pp65 antigenemia (p\ 0.0001). In mul-
tivariate analysis using time-dependent covariate functions for the de-
velopment of grades II-IV acute graft-versus-host disease (GvHD),
chronic GvHD, and pp65 antigenemia, CMV replicative status was
confirmed as a strong independent predictor of relapse (hazard ratio
[HR]: 0.19, 95 % CL: 0.08–0.44, p\ 0.0001) together with chronic
GvHD (HR: 0.23, 95%CL: 0.13-0.42, p\0.0001), and disease stage
(HR: 1.56, 95% CL: 1.22-2.06, p\0.0005). The antileukemic effect
was detectable across all prognostic genetic AML subsets and was par-
ticular pronounced in pts with intermediate/unfavourable karyotypes
(10-year CIR: 48 % without vs. 10 % with pp65 antigenemia, p\
0.0001). It was completely conserved in a 100-day landmark analysis
of relapse-free surviving pts (n 5 238) in multivariate analysis. This
translated into superior overall survival (OS) and event-free survival
(EFS) estimates at 10 years for pts with early CMV replication (OS:
63 % with vs. 36 % without pp65 antigenemia, p\ 0.0005; EFS: 63
% with vs. 38 % without pp65 antigenemia, p\ 0.0005). In conclu-
sion, this is the first report which demonstrates a strong and indepen-
dent effect of early CMV replication on the leukemic relapse risk in
a homogeneous population of adult AMLpts. This effect deserves fur-
ther andmore comprehensive studies to elucidate its clinical relevance
and the underlying antileukemic mechanisms.29
GENETIC VARIATION IN DONOR CTLA-4 REGULATORY REGION IS ASSO-
CIATED WITH RELAPSED FREE SURVIVAL AND OVERALL SURVIVAL
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Relapse is a major cause of mortality after allogeneic hematopoi-
etic cell transplant (allo-HCT). Graft-versus-tumor effect is medi-
ated primarily by T-cells. CTLA-4 is a critical inhibitor of T-cell
proliferation. Single nucleotide polymorphisms (SNPs) in CTLA-
4 have been associated with various autoimmune disorders and solid
organ allograft rejection. We hypothesized that genetic variation in
donor CTLA-4 would impact relapse-free survival (RFS) and overall
survival (OS) of recipients after allo-HCT independent of chronic
graft-versus-host disease (cGVHD) status.
Adult patients undergoing allo-HCT (cord transplant excluded) at
a single center (1999-2008), with a minimum survival of 120 days,
and with the availability of pre-transplant recipient and donor
germline DNA samples were included (n 5 164). Ten tagSNPs of
the CTLA-4 gene (rs231775, rs231779, rs11571315, rs231777,
rs3087243, rs16840252, rs231725, rs4553808, rs10197010,
rs11571316) were identified using previously published criteria. All
SNPs analyzed passed quality control [test ofHardy-Weinberg equi-
librium (HWE) P . 0.001, MAF . 0.10, SNP call rate . 0.95, and
pair-wise r2 value less than 0.8].
Table 1 outlines the patient characteristics. In univariate analyses,
the donor SNP rs4553808 A/A genotype was associated with
S162 Oral Presentationsimproved RFS (P5 0.019) andOS (P5 0.033) compared to the A/G
or G/G genotype. Multivariable analysis, adjusted for stem cell
source (peripheral blood vs. bone marrow), GVHD subtype (clas-
sic/overlap vs. acute subtypes/none), and disease risk (low vs. inter-
mediate vs. high) were performed to test the association of the
significant SNPs with RFS and OS. rs4553808 A/A genotype (HR
2.44, P 5 0.015), classic/overlap GVHD (HR 2.98, P 5 0.002)
and low/intermediate disease risk (HR 2.16, P5 0.03) were indepen-
dent predictors of superior OS. rs4553808 A/A genotype (HR 2.39,
P 5 0.016), and classic/overlap GVHD (HR 3.84, P 5 0.001) were
independent predictors of superior RFS.
Our study confirms reports that genetic variation in donor CTLA-
4 is associated with outcome after allo-HCT and may allow for
identification of patient subsets that may benefit from pre-emptive
modulation of immunosuppressive therapy. Further investigation
into the CTLA-4/ICOS/CD28 and B7 regulation of T cell homeo-
stasis is warranted to design a risk adapted approach to decrease the
mortality for patients with a high risk of relapse.
Table 1. Patient characteristics and survival of all patients.
(N5164)
N(%)VariableGVHD subtypeTotal Cohort
(N5164)Classic plus
Overlap
cGVHD N(%)
(N5101)aGVHD subtypes
plus No GVHD N
(%) (N563)Age, median
in years (range)47(18-69) 49(21-67) 46(18-69)GenderMale (R) 80(49) 49(49) 31(49)Female (R) 84(51) 52(51) 32(51)Female D to male R 31(19) 21(21) 10(19)RaceCaucasian (R/D) 156(95)/153(93) 94(93)/92(91) 62(98)/61(97)DiagnosisAcute Leukemia 86(52) 49(49) 37(59)Chronic Leukemia 19(12) 11(11) 8(13)Lymphoma 54(33) 38(37) 16(25)other 5(93) 3(3) 2(3)Disease Risk #Low 65(40) 38(38) 27(43)Intermediate 30(18) 21(20) 9(14)High 40(24) 25(25) 15(24)Missing 29(18) 17(17) 12(19)Stem Cell SourceMarrow 44(27) 23(22) 21(33)Peripheral Blood 120(73) 78(78) 42(67)Regimen IntensityMyeloablative 111(68) 69(68) 42(67)Other 53(32) 32(32) 21(33)Donor TypeRelated 109(67) 69(68) 40(63)Unrelated 55(33) 32(32) 23(37)HLA MatchHLA identical sibling 108(66) 68(67) 40(63)HLA matched unrelated 55(33) 32(32) 23(37)Other 1(1) 1(1) 0GVHD ProphylaxisCSA/MTX 112(68) 72(71) 40(63)CSA/MMF 50(31) 28(28) 22(36)Other 2(1) 1(1) 1(1)TBIYes 79(48) 52(51) 27(43)No 85(52) 49(49) 36(57)CMVR/D (+/+) 63(38) 35(34) 28(44)R/D (+/-) 19(12) 12(12) 7(11)R/D (-/+) 49(29) 29(29) 18(29)R/D (-/-) 35(21) 25(25) 10(16)Post-transplant Characteristics
(Continued )Table 1. (Continued )VariableN(%)
GVHD subtypeTotal Cohort
(N5164)Classic plus
Overlap
cGVHD N(%)
(N5101)aGVHD subtypes
plus No GVHD N
(%) (N563)aGVHDVGrade 0-2 vs. 3-4 179(78) vs. 32(20) 78(77) vs. 21(21) 51(81) vs. 11(7)Grade 0-1 vs. 2-4 39(24) vs. 122(74) 39(24) vs. 75(74) 15(24) vs. 47(75)PLT (X10(9)/L at
day 100,
median (range)110(10-356) 105(17-244) 112(10-356)Total Bilirubin
(mg/dL) at day
100, median(range)0.8(0-3.6) 0.8(0-2.4) 0.9(0.2-3.6)Survival2 year OS: (95% CI) 63%(56-72) 73%(64-83) 48%(36-64)2 year RFSU: (95% CI) 61%(54-70) 73%(65-83) 41%(30-57)# Disease risk-based on Committee of International Bone Marrow
Transplant Registry (CIBMTR) risk criteria; V aGVHD-3 cases missing;
U RFS analyses includes death from non-relapse causes as competing
risk. GVHD-graft-versus-host disease; cGVHD-chronic GVHD;
aGVHD-acute GVHD; R-recipient; D-donor; HLA-Human Leukocyte
Antigen; CSA-cyclosporine; MTX-methotrexate; MMF-mycophenolate
moefitil; TBI-Total body irradiation; CMV-cytomegalovirus; PLT-platelet;
OS-overall survival; RFS-relapse free survival; CI-confidence interval.30
IMMUNOMONITORING OF TRANSPLANTED PATIENTS INFUSED WITH
MESENCHYMAL STROMAL CELLS (MSC) FOR TREATING STEROID-
REFRACTORY GvHD
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Although the usage of mesenchymal stromal cells (MSC) as ther-
apy for Graft versus Host Disease (GvHD) is constantly increasing,
studies on MSC efficacy have been scarcely corroborated by biolog-
ical analysis of patient response to cell infusion. We report the im-
munological monitoring of 9 patients with steroid-refractory
GvHD, receivingmultiple doses ofMSCs.GvHDpresented as acute
in 5 cases and chronic in 4 cases. After MSC therapy, 2 patients
showed complete response (CR), 4 patients showed partial response
(PR) whereas 3 patients did not respond (NR) to MSC infusion.
To better comprehend the immunomodulatory effects ofMSC in-
fusions, we studied GvHD plasmatic markers, inflammatory cyto-
kines and CD41 T-cell subsets circulating in the peripheral blood
(PB) of enrolled patients before MSC infusion and at day 7, 14 and
28 after cell therapy.
In accordance with clinical observations, in CR patients we ob-
served a dramatic decrease of three validated GvHD plasmatic
markers TNFRI, IL2Ra and elafin (Paczesny S et al. Blood 2009)
to the mean levels of Healthy Donors (HD). In particular, at day
28 after therapy, TNFRI decreased of 2 times, IL2Ra levels de-
creased of 1.9 times and elafin decreased of 2.3 times. Moreover, in-
vestigating the effect of MSC infusion on lymphocyte counts, we
observed in both CR patients a significant decrease in CD31 and
CD41 lymphocyte counts in the PB. Interestingly, after MSC infu-
sions, CD41 T-cell subsets changed significantly: Tregs increased
and Th1 and Th17 populations decreased. In particular, Th1/Treg
ratio decreased of 3.5 times and Th17/Treg ratio decreased of 3.6
times. Correspondingly, patient symptoms also gradually improved,
